NASDAQ: GRALGrail Inc Stock
$68.11-0.16 (-0.23%)
Updated Jul 1, 2026
GRAL Price
$68.11
Fair Value Price
N/A
Market Cap
$2.92B
52 Week Low
$29.95
52 Week High
$118.84
P/E
-6.61x
P/B
1.17x
P/S
13.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$156.12M
Earnings
-$395.33M
Gross Margin
-36.5%
Operating Margin
-330.27%
Profit Margin
-253.2%
Debt to Equity
0.12
Operating Cash Flow
-$291M
Beta
2.3
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GRAL Overview
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GRAL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
GRAL
Ranked#31 of 44
Ranked#31 of 44
Be the first to know about important GRAL news, forecast changes, insider trades & much more!
GRAL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GRAL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRAL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GRAL is good value based on its book value relative to its share price (1.17x), compared to the US Diagnostics & Research industry average (3.87x)
P/B vs Industry Valuation
GRAL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GRAL due diligence checks available for Premium users.
Valuation
GRAL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.61x
Industry
12.54x
Market
8.54x
GRAL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
3.87x
GRAL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRAL's financial health
Profit margin
Revenue
$40.8M
Net Income
-$93.2M
Profit Margin
-228.5%
GRAL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GRAL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.8B
Liabilities
$302.8M
Debt to equity
0.12
GRAL's short-term assets ($877.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRAL's short-term assets ($877.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRAL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$87.0M
Investing
-$93.4M
Financing
$0.0
GRAL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRAL vs Diagnostic & Research Stocks
Grail Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.